Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its
recent achievements as part of the company’s overall strategy to expand its
clinical development programs and bring its lead drug candidate, Oncoprex(TM)
immunogene therapy, to commercialization. Per the update, Genprex has published
recent as well as historical achievements to its newly launched,
interactive corporate timeline, which can be found on the company’s
website. “Since Genprex’s IPO last year, we have made significant progress in
many areas of the company, including progress toward expansion of our clinical
programs and sponsored research, our manufacturing process development and
scalability, and the growth of our team to support these initiatives,” Genprex
Chairman and Chief Executive Officer Rodney Varner said in the news release.
“These accomplishments have set the stage for us to continue on our path of
growth and expansion, enabling our efforts to bring our drug candidate to
market for lung cancer patients who cannot benefit from today’s therapies.”
To view the full press release, visit http://ibn.fm/6afhE
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex’s platform technologies are designed to administer
cancer fighting genes by encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken up by tumor
cells where they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts cell
signaling pathways that cause replication and proliferation of cancer cells,
re-establishes pathways for apoptosis, or programmed cell death, in cancer
cells, and modulates the immune response against cancer cells. Oncoprex has
also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
